Microsoft and NVIDIA drive innovation in healthcare and life sciences

The partnership combines the global scale, security and advanced computing capabilities of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite of computing platforms, software and services. The goal is clear: to accelerate innovation in healthcare and life sciences and improve patient care.

Faster, more accurate drug discovery

The collaboration, to drive innovation in healthcare and life sciences, focuses on three main areas:

• Drug Discovery: NVIDIA’s BioNeMo platform, hosted on the NVIDIA DGX Cloud on Azure, provides a faster path to developing and deploying AI models, accelerating drug discovery. The platform analyzes vast data sets with unprecedented speed and accuracy, helping scientists identify potential drug candidates more efficiently.

Improve clinical research and patient care

• Image diagnosis: The combination of Azure, NVIDIA MONAI (Medical Open Network for AI), and Nuance Precision Imaging Network (PIN) enables the safe and effective development, validation, deployment, and evaluation of medical imaging AI models at scale. This allows developers to create high-performance models, healthcare providers to deploy a single platform to run multiple models, and researchers to accelerate drug discovery.

Simplified and scalable genomic analysis

• Genomic analysis: The SOPHiA DDM Software-as-a-Service platform, hosted on Azure, will be powered by NVIDIA Parabricks for the SOPHiA DDM full-genome application. This offers a simplified, scalable and comprehensive whole-genome analytical solution.

Democratizing AI for healthcare professionals

Microsoft is also working with NVIDIA to deliver a future suite of NVIDIA healthcare microservices on Azure AI. This will enable researchers, clinicians and developers to explore and deploy next-generation models, democratizing the adoption of AI in healthcare.

Innovation in healthcare and life sciences: A new era

The combination of Microsoft and NVIDIA technologies has the potential to revolutionize and drive innovation in healthcare and life sciences.

The expanded partnership aims to accelerate advances in clinical research, drug discovery and care delivery, propelling the industry into an exciting new era of medicine.

Other interesting articles: